2 weeks Ago By ABMN Staff
Lipella Pharmaceuticals ( NASDAQ:LIPO – Get Free Report ) is one of 1,049 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its competitors? We will compare Lipella Pharmaceuticals to similar businesses based on the strength of its risk, profitability, analyst recommendations, institutional ownership, valuation, dividends and earnings. Profitability This table compares Lipella Pharmaceuticals and its competitors’ net margins, return on equity and return on assets. Analyst Recommendations This is a summary of recent ratings and price targets for Lipella Pharmaceuticals and its competitors, as provided by MarketBeat.
Volatility and Risk Lipella Pharmaceuticals has a beta of 0.31, meaning that its stock price is 69% less volatile than the S&P 500. Comparatively, Lipella Pharmaceuticals’ competitors have a beta of 1.
05, meaning that their average stock price is 5% more volatile than the S&P 500. Valuation & Earnings This table compares Lipella Pharmaceuticals and its competitors top-line revenue, earnings per share (EPS) and valuation. Lipella Pharmaceuticals’ competitors have higher revenue and earnings than Lipella Pharmaceuticals.
Lipella Pharmaceuticals is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry. Institutional and Insider Ownership 74.3% of Lipella Pharmaceuticals shares are owned by institutional investors.
Comparatively, 44.3% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 32.
1% of Lipella Pharmaceuticals shares are owned by company insiders. Comparatively, 13.8% of shares of all “Pharmaceutical preparations” companies are owned by company insiders.
Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Summary Lipella Pharmaceuticals beats its competitors on 8 of the 13 factors compared. About Lipella Pharmaceuticals ( Get Free Report ) Lipella Pharmaceuticals Inc.
, a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc.
was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania. Receive News & Ratings for Lipella Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipella Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter .
.
